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Monoclonal antibodies (MAbs) specific for the P domain of the Plasmodium falciparum P0 phosphoribopro-
tein (PfP0) blocked the invasion of RBCs by P. falciparum. Vaccination with this P-domain peptide protected
mice upon malaria parasite challenge. The absolute specificity of the MAbs and the PfP0 P peptide makes them
potential protective malaria reagents.
Ribosomal phosphoprotein P0 is a neutral protein that is
found in all eukaryotes (17). P0 is related to the family of acidic
ribosomal phosphoproteins P1 and P2, and these three pro-
teins collectively constitute the ribosomal P proteins. The P
proteins possess a highly homologous carboxy-terminal do-
main (the P domain) and also complex together as (P1)2-P0-
(P2)2 to form the GTPase binding stalk region of the 60S
ribosomal subunit of eukaryotes (18, 25, 26). Of the three
ribosomal P proteins, P0, but not P1 or P2, is a vital protein as
demonstrated by knockout studies in Saccharomyces cerevisiae
(19).
P proteins have been shown to be immunogenic and have
been studied extensively in humans because of their associa-
tion with systemic lupus erythematosus (SLE), an autoimmune
disorder. Approximately 10 to 15% of patients suffering from
SLE possess autoantibodies against the conserved carboxy-
terminal 22 amino acids of the P proteins (4). The reactive
domain has been narrowed to 11 amino acids (11), and re-
cently, it was narrowed to the 6 amino acid residues at the
carboxy-terminal ends of the P proteins (14). The roles of these
anti-P-protein antibodies in the pathogenesis of SLE disease
are not clear. The ribosomal protein P0 can act as an immuno-
gen, since P0 has been shown to be located on the surfaces of
Plasmodium, Toxoplasma gondii, and S. cerevisiae as well as on
the surfaces of neuronal, hepatic, and other cell lines using
cross-reactive antibodies (9, 12, 23). In some of these studies,
the surface reactivity was attributed to a P0-like determinant,
since a cross-reactivity of anti-P0 polyclonal antibodies to other
protein(s) could not be ruled out (23). By transfecting T. gondii
cells with tagged T. gondii P0 phosphoriboprotein (TgP0), Se-
hgal et al. recently demonstrated that the cognate TgP0 pro-
tein translocates to the cell surface (20).
Specific antibody responses against the P0 protein of proto-
zoan parasites have been shown to be prevalent among people
with chronic parasitic infections (1, 2, 13, 24). Eighty-seven
percent of adult residents in areas of eastern India where
malaria is endemic possess antibodies against Plasmodium fal-
ciparum P0 phosphoriboprotein (PfP0) (13). Approximately
60% of adults residing in Kenya showed T-cell responses to the
PfP0 protein, and the magnitude of this response was compa-
rable to the T-cell responses to MSP-1 protein, a candidate
vaccine antigen (I. Malhotra, P. Mungai, J. Ouma, S. Sharma,
J. W. Kazura, and C. L. King, unpublished data). In the case of
Trypanosoma cruzi, it has been shown that antibodies against
the P domain were present in a large proportion of cardiac
chagasic patients (2). Seventy-four percent of Toxoplasma pa-
tients showed the presence of anti-Toxoplasma P0 antibodies
(1). For dogs with visceral leishmaniasis, 78% of infected sera
were shown to possess Leishmania infantum P0-specific anti-
bodies (24). The L. infantum acidic ribosomal protein P0 has
recently been shown to confer protective immunity to Leish-
mania major infection in BALB/c mice (10). Polyclonal anti-
bodies against PfP0 have been shown to block the parasite
invasion of red blood cells (RBCs) (3).
Cross-reactivity of parasite and human P0 (HuP0) proteins
has been reported earlier (5, 11, 22). Although antibodies to
ribosomal P proteins of Trypanosoma cruzi in Chagas’ disease
differed from anti-P-protein autoantibodies in lupus, these an-
tibodies were found to possess functional autoreactivity with
heart tissue (11). Antibodies found in SLE patients show dis-
tinct cross-reactivity and inhibit P. falciparum culture through
specific reactivity with PfP0 protein (5, 22). Anti-PfP0 antibod-
ies and other autoantibodies are prevalent in adult residents of
areas where malaria is endemic, but there is no apparent link-
age to SLE disease in these regions (13). The correlation of
human anti-P-protein antibodies to SLE disease progression is
not clear (14). However, since disease progression has been
postulated to be correlated with anti-P-protein antibodies in
some of the studies (7, 16), it is imperative to elucidate the
parasite-specific protective immune response. To obtain para-
site-specific reagents, monoclonal antibodies (MAbs) were
raised against the recombinant PfP0 protein. In this paper, we
show that three of these MAbs were protective and reacted
very specifically to the parasite P0 protein. Using active and
passive immunizations, we demonstrate that the 16-amino-acid
C-terminal peptide sequence (P peptide) of PfP0 is protective
and that the response is very specific for the parasite protein.
The MAbs were generated against the recombinant carboxy-
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terminal region of P0 (PfPOC; amino acids 61 to 316), which
was purified as described earlier (3). Approximately 50 g of
this purified PfP0 protein emulsified with Freund’s adjuvant
was administered intraperitoneally into 6-week-old female
BALB/c mice. After four weekly injections, the mice were
immunized on a monthly basis. Five days before fusion of
splenocytes with mouse myeloma Sp2/0 cells, the mice were
immunized once with 250 g of immunogen in phosphate-
buffered saline (PBS). Antibody-secreting clones were selected
by an enzyme-linked immunosorbent assay (ELISA) using im-
mobilized glutathione S-transferase (GST)-PfP0C protein. Of
the 12 hybrid clones that showed exclusive reactivity to PfP0C,
7 were subcloned to monoclonality by limiting dilutions, yield-
ing 7 pure clones. MAbs 2C1E2 and 2C2F3 mapped to amino
acid residues 61 to 182 and 61 to 281, respectively, and MAb
5B2F10 mapped to residues 183 to 281 of PfP0, while MAbs
1B3H3, 1E5F4, 2G1D4 and 2H1B12 mapped to the linear P
domain (Fig. 1). Thus, MAbs reactive to the extreme carboxy-
terminal 16-amino-acid domain of PfP0 were prevalent among
the MAbs generated, strengthening the enhanced immuno-
genic status of the extreme carboxy-terminal domain of P0
protein.
Specificity of reactivity of the MAbs to the parasite P0 pro-
tein. To test the binding of the MAbs to the PfP0 protein and
to check the cross-reactivity of the MAbs with (i) the murine
malaria parasite Plasmodium berghei, (ii) the closely related
apicomplexan parasite T. gondii, and (iii) the HuP0 proteins,
immunoblotting and immunofluorescence assay (IFA) were
performed. Asexual stages of P. falciparum (3D7 strain) were
cultured in vitro as described earlier (6). Parasites were main-
tained in 5% hematocrit in complete RPMI at 37°C in a hu-
midified chamber containing 5% CO2. The P. berghei ANKA
strain was maintained by passaging asexual stages through
BALB/c mice by intraperitoneal injections. Intracellular para-
sites were liberated from infected erythrocytes by treatment
with 0.15% saponin (3). The parasite pellet was solubilized
with 5 volumes of PBS buffer containing 1% Triton X-100, and
the supernatant and the particulate fractions, normalized to
equal volumes, were used for Western blot analysis. Parasite
protein extract from approximately 105 parasites/lane was elec-
FIG. 1. (I) Schematic representation of PfP0 protein with domains recognized by the MAbs. The sequences of conserved P0 P peptides are
shown. The P0 P peptides conserved in P. falciparum, P. vivax, P. yoelii, and P. berghei (Pf/Pv/Py/Pb), humans and mice (Hu/Mo), and T. gondii (Tg)
are shown. (II) Immunoblot analysis. Western blots of total protein extracts of P. falciparum (A), P. berghei (B), T. gondii (C), and human
lymphocytes (D) with various MAbs are shown. The extracts were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10%
polyacrylamide gels) under reducing conditions. (A) P. falciparum particulate (lanes 1) and supernatant (lanes 2) fractions, probed with MAb
5B2F10 (a and b) and control Sp2/0 culture supernatants (c). A shorter (a) and longer (b) exposure of the enhanced chemiluminescence reaction
for the same immunoblot is shown. (B) P. berghei protein extract probed with culture supernatants of different MAbs. Lanes: 1, MAb 2C1E2; 2,
MAb 2C2F3; 3, MAb 5B2F10; 4, MAb 1E5F4; 5, control Sp2/0. (C) T. gondii total protein probed with pooled MAbs (lane 1), polyclonal anti-PfP0
antibodies (diluted 1:100) (lane 2), and anti-SAG1 antibodies (diluted 1:5,000) (lane 3). (D) Human lymphocyte extract (lanes 1) and P. berghei
protein extract (lanes 2) using goat anti-human dynamin antibody (diluted 1:1,000) (a) and pooled MAbs (b). The positions of the respective P0
proteins (arrows and arrowheads) and the 100-kDa dynamin protein (asterisk) are indicated.
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trophoresed on a 10% polyacrylamide gel under reducing con-
ditions. Proteins were transferred onto nitrocellulose paper
and probed with the MAbs, followed by incubation with horse-
radish peroxidase-conjugated rabbit anti-mouse immunoglob-
ulin, and immunoreactive bands were visualized with 3,3-dia-
minobenzidine (Sigma). T. gondii was cultured, and tachyzoites
were harvested for immunoblotting and IFA as described ear-
lier (20).
To determine whether the MAbs cross-reacted with HuP0,
immunoblotting of protein extract from human lymphocytes
was done. Human blood was collected with the anticoagulant
EDTA, and the lymphocytes were separated by centrifugation
at 600  g for 15 min at 4°C on Histopaque 1077 density gra-
dient (Sigma Diagnostics, Inc.). The buffy coat was used as the
source of human lymphocytes. Crude protein extract was ob-
tained by sonication of the lymphocytes in PBS containing
pepstatin (1 g/ml) and leupeptin (1 g/ml).
Immunoblot analysis of each of the seven MAbs with total
P. falciparum protein extract showed a single band of reactivity
to the 38-kDa P0 protein. Figure 1, panel IIA, shows a repre-
sentative sample of such an immunoblot using MAb 5B2F10.
Most of the PfP0 protein was found in the soluble supernatant
fraction, but there was approximately 10% residual activity in
the particulate fraction as well (Fig. 1, panel IIA). This is
consistent with the surface localization property of this protein
(3). Total crude protein extract from P. berghei showed distinct
cross-reactivity with each MAb (Fig. 1, panel IIB). Neither the
T. gondii tachyzoites nor the human lymphocytes showed any
reactivity with the pooled MAbs (Fig. 1, panels IIC and D).
However, the same preparation reacted with standard marker
antibodies, ensuring proper protein preparation and immuno-
screening procedure. The murine malaria parasites P. berghei
and Plasmodium yoelii P0 proteins and the other human ma-
laria parasite Plasmodium vivax P0 protein show 86% iden-
tity and 94% similarity to PfP0 (www.PlasmoDB.org), and
the P-peptide domain is identical for each of these parasites
(Fig. 1). TgP0 protein is also very similar to PfP0 (20), and the
polyclonal antibodies to PfP0 show cross-reactivity with the
TgP0 protein extract (Fig. 1, panel IIC). However, the nonre-
activity of the MAbs with TgP0 indicates that there are distinct
conformational differences in the Plasmodium and Toxoplasma
P0 proteins. The P-peptide sequence of TgP0 is quite distinct
from that of PfP0 and is identical to the other unicellular
protozoan parasites, such as Leishmania and Trypanosoma
(Fig. 1).
MAbs 2C1E2, 2C2F3, 5B2F10, and 2H1B12 (one MAb for
each of the four classes reactive to different domains of PfP0)
were used for IFA, flow cytometric analysis, and invasion-block-
ing assays. IFA was performed with P. falciparum and T. gondii
as described earlier (20, 21). Briefly, slides coated with the
parasites were air dried and fixed for 5 min with chilled meth-
anol. After blocking of the slides with 100 g of bovine serum
albumin (BSA) per ml, the slides were incubated with the
hybridoma culture supernatants for 1 h. This was followed by
incubation with Alexa Fluor 488 goat anti-mouse immuno-
globulin G (IgG) (heavy plus light chains) (Molecular Probes)
for 30 min. 4,6-Diamidino-2-phenylindole (DAPI) (Boehr-
inger Mannheim) (0.5 g/ml) was used for 1 min for double
staining of the slides. Confocal microscopy was performed
using a Bio-Rad Radiance imaging system mounted on a Ni-
kon inverted microscope. An argon laser with a wavelength of
488 nm was used as the excitation source. The samples were
viewed using 100 oil immersion objective lens.
A representative IFA reactivity with MAb 5B2F10 is shown
in Fig. 2. A ring stage is shown in Fig. 2a to d. In this early
stage, the PfP0 protein appears in the thin cytoplasmic region.
In later stages, the reactivity is observed all over the parasite
(Fig. 2e and f). Maximum reactivity of the MAbs was observed
with the trophozoite and schizont stages, which is consistent
with the transcription profile of PfP0 (6) (http://PlasmoDB
.org). No reactivity was seen with the control Sp2/0 culture
supernatant (Fig. 2g and h), RBCs (Fig. 2e and f), or lympho-
cytes (data not shown). No reactivity was seen with T. gondii
tachyzoites with any of these four MAbs (Fig. 2i to k).
To further rule out any cross-reactivity of the MAbs to
native HuP0, flow cytometric analysis was performed using
human lymphocytes (Fig. 3). Human lymphocytes, obtained
from the buffy coat after Histopaque density gradient centrif-
ugation, were fixed with 4% paraformaldehyde for 10 min, and
permeabilized for 10 min using PBS containing 1.5% Triton
X-100 and 2% fetal bovine serum. Aliquots containing 106 cells
per 100 l of PBS containing 2% fetal bovine serum were
FIG. 2. Immunofluorescence of P. falciparum asexual stages and T.
gondii tachyzoites. Ring (a to d) or schizont (e to h) stages of P.
falciparum with the culture supernatants of 5B2F10 (a to f) and Sp2/0
(g and h). Panels a to d and panels e and f show the same views,
respectively, with panels d and e representing the corresponding bright
fields. P. falciparum ring stage was stained with DAPI (a) and MAb
5B2F10 (b). Panel c shows a merged view of panels a and b, with
nonoverlapping staining. (i to k) T. gondii tachyzoites by bright-field
microscopy (i), with pooled MAbs (j), and with DAPI stain (k). DAPI
stain and Alexa Fluor 488 goat anti-mouse IgG stain were used. Bar, 5
m.
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incubated for 30 min with purified mouse IgG1() (BD Pharm-
ingen) as an isotype control and with various anti-PfP0 anti-
bodies. In each of the treatments, MAbs were used at a con-
centration of 1 g of protein per 106 cells. This was followed by
incubation with Alexa Fluor 488 goat anti-mouse or anti-rabbit
IgG (heavy plus light chains) (Molecular Probes) for 45 min.
All the steps were performed on ice. Labeled cells were ana-
lyzed in a flow cytometer (Partec PAS) using Partec Flowmax
software. No reactivity was observed with the pooled MAbs
(Fig. 3A). The cross-reactive mouse and rabbit polyclonal an-
tisera against PfP0 protein (23) showed significant reactivity
with the same lymphocyte population under the same condi-
tions (Fig. 3B and C).
Invasion-blocking assay. Asexual stages of P. falciparum
were cultured in vitro as described earlier (3). The invasion-
blocking assay was performed in triplicate in 96-well sterile
tissue culture plate (Nunc, Roskilde, Denmark) in a total cul-
ture volume of 200 l. P. falciparum, synchronized by repeated
sorbitol treatment (21) at a parasitemia of 1 to 2% with 5%
hematocrit, was incubated with MAbs 2C1E2, 2C2F3, 5B2F10,
and 2H1B12 concentrated by 50% ammonium sulfate precip-
itation of ascitic fluid. With recombinant GST-PfP0C protein
at a concentration of 50 g/ml, MAbs 2C1E2 and 2H1B12
bound to up to 30 ng of the protein, while MAbs 2C2F3 and
5B2F10 bound to as little as 7 ng of the protein (data not
shown). Hence, MAbs 2C1E2 and 2H1B12 were used at a
concentration of 400 g/ml, while the other two MAbs were
used at 100 g/ml.
RBC smears were made at different time points and stained
with Giemsa, and parasitemia was measured by microscopic
counting. Three independent experiments were performed for
each treatment, and at least two sets of 5,000 RBCs were
counted for each experiment at every time point (Fig. 4).
Results of invasion-blocking assay were subjected to statistical
analysis. The means of experimental groups were compared
using one-way analysis of variance (GraphPad InStat, San Di-
ego, Calif.). The means were considered statistically signifi-
cantly different if the P values were 0.05. RBC smears were
counted at different stages, rings, trophozoites, and schizonts
FIG. 3. Flow cytometric analysis of fixed and permeabilized human lymphocytes. (A) Purified mouse IgG1() isotype control and pooled MAbs
were used. (B and C) Mouse (Mou.) and rabbit (Rab.) preimmune serum (a) and mouse and rabbit polyclonal anti-GST-PfP0C antibodies (b) were
used. The mean fluorescence intensity (MFI) for specific anti-P0 staining over control staining is indicated.
FIG. 4. Invasion-blocking assay. Synchronized P. falciparum cul-
tures were treated with different antibodies as described in the text.
MAbs 2C1E2 (C1), 2H1B12 (H1), and Sp2/0 (S) were used at 400
g/ml, while MAbs 2C2F3 (C2) and 5B2F10 (B2) were used at 100
g/ml. An untreated control culture (C) is shown. Percent inhibition in
parasitemia after 55 h is depicted. The values were considered statis-
tically significantly different if the P values were 0.05. Values are
expressed as means  standard errors of the means (error bars).
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until the next ring stage. No significant differences in para-
sitemia were observed up to the schizont stage. However, there
were significant differences in parasitemia in the control and
antibody-treated wells in the smears made after 55 h, when
most of the parasites were in the ring stage (Fig. 4). At a final
concentration of 400 g/ml, MAbs 2C1E2 and 2H1B12 inhib-
ited parasitemia by approximately 35 and 52%, respectively.
MAbs 2C2F3 and 5B2F10, used at 100 g/ml, inhibited para-
sitemia by 23 and 18%, respectively. No inhibition was seen in
the wells with Sp2/0 preparation (400 g/ml). All the MAbs
except 5B2F10 showed significant inhibition (P  0.05).
Vaccination studies with PfP0 P peptide in mice. MAbs
reactive to the extreme carboxy-terminal 16-amino-acid do-
main of PfP0 were prevalent among the MAbs generated.
Moreover, the anti-PfP0 P-peptide MAb 2H1B12 was the most
effective inhibitor of parasite invasion. It was also observed
that all four MAbs as well as three other parent lines (7 of 12
total lines tested) reacted specifically with the linear PfP0 P-
peptide epitope in ELISA, while they did not react with the
equivalent P0 P-peptide epitope conserved in mice and hu-
mans (data not shown). Therefore, we decided to test the PfP0
P peptide in vaccination studies in mice.
The PfP0 P peptide was coupled to BSA (PfP0 P-BSA) using
glutaraldehyde (15). Experiments were performed on three
groups of 8-week-old female Swiss mice (six or seven mice per
group). Mice were injected intraperitoneally with PfP0 P-BSA
conjugate in Freund’s adjuvant at 21-day intervals. In one
control group, mice were injected in parallel with PBS emul-
sified in Freund’s adjuvant. The other control group received
no injections. After five immunizations, the titers of the anti-
PfP0 antibodies were measured, and the mice were challenged
with P. yoelii (106 parasites per mouse), and parasitemia was
monitored daily.
Figure 5 shows the parasitemia profile of each mouse over a
period of 31 days after challenge in the three groups. All 14
control mice developed parasitemia by the sixth day postchal-
lenge (Fig. 5A and B). Figure 5D shows the average para-
sitemia values for each treatment. The highest average para-
sitemia values were 45 and 32% on day 17 for mice injected
with adjuvant and unimmunized mice, respectively. Of the
seven adjuvant-treated mice, two mice died on day 6 and day
17. Of the seven control mice that received no immunization,
one mouse died on day 20. However, of the six mice immu-
nized with PfP0 P peptide, only two mice developed para-
FIG. 5. Vaccination of mice with PfP0 P peptide. The parasitemia profile of each mouse over a period of 31 days is shown. Mice were injected
with adjuvant (A) or not injected (B) for controls or injected with PfP0 P-BSA conjugate (C). (D) Average parasitemia values over a period of
31 days. The parasitemia values were considered statistically significantly different if the P values were 0.05. (E) Reactivity of antisera from mice
immunized with PfP0 P-BSA to PfP0 P and MoP0 P peptides.
VOL. 72, 2004 NOTES 5519
sitemia that was detected throughout the study. One mouse
showed parasitemia on day 7 and died on day 8 when para-
sitemia was approximately 47%. This mouse had the lowest
titer of antibodies to PfP0 P peptide (Fig. 5E). The other
mouse showed a delayed parasitemia from day 14 and showed
a peak value of approximately 50% on day 26. However, this
mouse recovered by day 31. None of these mice showed reac-
tivity to MoP0 P peptide (Fig. 5E). Mean parasitemia levels of
the three groups were compared using one-way analysis of
variance (GraphPad InStat). The means were considered sta-
tistically significantly different if the P values were 0.05. Dif-
ferences in the mean parasitemia levels were extremely signif-
icant on day 9 (P  0.0001), day 11 (P 	 0.0014), day 13 (P 	
0.0007), day 15 (P 	 0.003), and day 17(P 	 0.023).
To monitor possible long-term effects of immunization with
the PfP0 P peptide, sera were collected from these mice 4
months after parasite challenge. While the sera continued to
be positive for PfP0 P peptide (average titer, 1:2,000), they
showed no reactivity to MoP0 P peptide (data not shown).
Repeated vaccination studies with PfP0 P peptide showed sim-
ilar results, with the extent of protection correlating with the
titer of anti-P-peptide antibody. Initial vaccination studies
were performed with mice after four immunizations of the
antigen. The titers of the anti-PfP0 P antibodies were less than
1:2,000 (data not shown). Significant protection was not seen
when the mice were subjected to parasite challenge. Hence,
subsequent trials were performed after five immunizations
with the antigen.
A comparison of the P-peptide sequence of the P0 protein
conserved in humans and mice and the Plasmodium P0 protein
reveals a difference of 5 amino acids in the last 16-amino-acid
stretch (Fig. 1, panel I). In the last six amino acids, GFGLFD
(HuP0) versus GFGMFD (PfP0), there is just one amino acid
difference. The amino acids crucial for SLE serum reactivity
are postulated to be the two phenylalanine residues (14). Al-
though these two phenylalanine residues are conserved in the
Plasmodium P0, neither the MAbs nor the polyclonal sera
from vaccinated mice reacted with the mammalian P peptide.
However, the SLE serum samples do react with the PfP0 16-
amino-acid P peptide in an ELISA (A. B. Mannan and S.
Sharma, unpublished data). Thus, although the postulated
6-amino-acid SLE target P domain is nearly identical between
PfP0 and HuP0, there appears to be a significant difference
between the antibodies produced in SLE patients compared to
the immune response generated upon P-peptide immuniza-
tion. The other four amino acids, which are different in the
HuP0 and PfP0 16-amino-acid P peptides, are radical changes
from uncharged to charged amino acids (Fig. 1); these changes
are likely to confer considerable structural differences between
the HuP0 and PfP0 peptides. A notable difference between
PfP0 and the mammalian P peptide is the absence of the serine
residues at positions 303 and 306. These residues have been
shown to be phosphorylated in mammals and are postulated
to play important target residues for regulatory structural
changes (8). Thus, despite the 69% identity between the P
peptides of Plasmodium and mammalian species, the P epi-
topes appear to be structurally and functionally different be-
tween these species.
The closely related apicomplexan and protozoal parasites
appear to have other structures for the P peptide. In the T.
gondii P peptide, six amino acids are different compared to the
Plasmodium P-peptide sequence, with a proline residue replac-
ing a charged amino acid (Fig. 1). This proline residue is
observed in other protozoan species as well (10, 11). The func-
tional relevance (if any) for the differences for these three sets
of P peptide is not clear as yet. However, with distinct differ-
ences in the P peptides of mammals and other protozoans, but
with the conservation among all the Plasmodium P0 proteins,
this linear epitope should be able to target all forms of malaria
specifically. The invasion-blocking parasite-specific MAbs and
vaccination data presented here demonstrate malaria-specific
protective properties of the PfP0 P peptide. With the current
scenario of emerging drug resistance to virtually every existing
drug against malaria, it may be worthwhile to explore the PfP0
P epitope towards therapeutic and prophylactic control of ma-
laria.
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